{
    "xml": "<topic id=\"PHP3124\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/tolcapone\" basename=\"tolcapone\" title=\"TOLCAPONE\">\n<title>TOLCAPONE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1042\" namespace=\"/interactions/list-of-drug-interactions/dopaminergics/tolcapone\">Tolcapone</xref>\n</p>\n<data name=\"vtmid\">108464002</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_743470528\" title=\"Catechol-o-methyltransferase inhibitors\">Catechol-o-methyltransferase inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP37986\" outputclass=\"drugAction\" rev=\"1.8\" parent=\"/drugs/tolcapone\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Tolcapone prevents the peripheral breakdown of levodopa, by inhibiting catechol-<i>O</i>-methyltransferase, allowing more levodopa to reach the brain.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35177\" outputclass=\"indicationsAndDose\" rev=\"1.12\" parent=\"/drugs/tolcapone\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Adjunct to co-beneldopa or co-careldopa in Parkinson's disease with 'end-of-dose' motor fluctuations if another inhibitor of peripheral catechol-O-methyltransferase inappropriate (under expert supervision)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>100&#8239;mg 3 times a day (max. per dose 200&#8239;mg 3 times a day) continuing beyond 3 weeks <b>only</b> if substantial improvement, leave 6 hours between each dose; first daily dose should be taken at the same time as levodopa with dopa-decarboxylase inhibitor, dose maximum only in exceptional circumstances.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38013\" outputclass=\"contraindications\" rev=\"1.11\" parent=\"/drugs/tolcapone\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Phaeochromocytoma</ph>; <ph outputclass=\"contraindication\">previous history of hyperthermia</ph>; <ph outputclass=\"contraindication\">previous history of neuroleptic malignant syndrome</ph>; <ph outputclass=\"contraindication\">previous history of rhabdomyolysis</ph>; <ph outputclass=\"contraindication\">severe dyskinesia</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38036\" outputclass=\"cautions\" rev=\"1.15\" parent=\"/drugs/tolcapone\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Most patients receiving more than 600&#8239;mg levodopa daily require reduction of levodopa dose by about 30%</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Hepatotoxicity</p>\n<p>Potentially life-threatening hepatotoxicity including fulminant hepatitis reported rarely, usually in women and during the first 6 months, but late-onset liver injury also reported; discontinue if abnormal liver function tests or symptoms of liver disorder; do not re-introduce tolcapone once discontinued.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35170\" outputclass=\"interactions\" rev=\"1.9\" parent=\"/drugs/tolcapone\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (tolcapone).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35125\" outputclass=\"sideEffects\" rev=\"1.17\" parent=\"/drugs/tolcapone\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">anorexia</ph>; <ph outputclass=\"sideEffect\">chest pain</ph>; <ph outputclass=\"sideEffect\">confusion</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">drowsiness</ph>; <ph outputclass=\"sideEffect\">dyskinesia</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">dystonia</ph>; <ph outputclass=\"sideEffect\">excessive dreaming</ph>; <ph outputclass=\"sideEffect\">hallucinations</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hepatotoxicity</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">sleep disturbances</ph>; <ph outputclass=\"sideEffect\">sweating</ph>; <ph outputclass=\"sideEffect\">syncope</ph>; <ph outputclass=\"sideEffect\">urine discoloration</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>; <ph outputclass=\"sideEffect\">xerostomia</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Neuroleptic malignant syndrome reported on dose reduction or withdrawal</ph>; <ph outputclass=\"sideEffect\">rhabdomyolysis reported on dose reduction or withdrawal</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35156\" outputclass=\"pregnancy\" parent=\"/drugs/tolcapone\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Toxicity in <i>animal</i> studies&#8212;use only if potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP38042\" outputclass=\"breastFeeding\" parent=\"/drugs/tolcapone\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP37963\" outputclass=\"hepaticImpairment\" parent=\"/drugs/tolcapone\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35138\" outputclass=\"renalImpairment\" parent=\"/drugs/tolcapone\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Caution if eGFR less than 30&#8239;mL/ minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35101\" outputclass=\"monitoringRequirements\" parent=\"/drugs/tolcapone\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Test liver function before treatment, and monitor every 2 weeks for first year, every 4 weeks for next 6 months and then every 8 weeks thereafter (restart monitoring schedule if dose increased).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35112\" outputclass=\"treatmentCessation\" rev=\"1.10\" parent=\"/drugs/tolcapone\">\n<title>Treatment cessation</title>\n<body>\n<section>\n<sectiondiv>\n<p>Avoid abrupt withdrawal.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP35150\" outputclass=\"patientAndCarerAdvice\" rev=\"1.14\" parent=\"/drugs/tolcapone\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patients should be told how to recognise signs of liver disorder and advised to seek immediate medical attention if symptoms such as anorexia, nausea, vomiting, fatigue, abdominal pain, dark urine, or pruritus develop.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP3124-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/tolcapone\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76922\" title=\"Tablet\" namespace=\"/drugs/tolcapone/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1042\" namespace=\"/interactions/list-of-drug-interactions/dopaminergics/tolcapone\" title=\"Tolcapone\" count=\"1\" rel=\"link\">Tolcapone</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76922\" namespace=\"/drugs/tolcapone/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP3124",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/tolcapone",
    "basename": "tolcapone",
    "title": "TOLCAPONE",
    "interactants": [
        {
            "id": "bnf_int_1042",
            "label": "Tolcapone"
        }
    ],
    "vtmid": "108464002",
    "drugClassification": [
        "Catechol-o-methyltransferase inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Tolcapone prevents the peripheral breakdown of levodopa, by inhibiting catechol-O-methyltransferase, allowing more levodopa to reach the brain.",
                "html": "<p>Tolcapone prevents the peripheral breakdown of levodopa, by inhibiting catechol-<i>O</i>-methyltransferase, allowing more levodopa to reach the brain.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Adjunct to co-beneldopa or co-careldopa in Parkinson's disease with 'end-of-dose' motor fluctuations if another inhibitor of peripheral catechol-O-methyltransferase inappropriate (under expert supervision)",
                        "html": "Adjunct to co-beneldopa or co-careldopa in Parkinson's disease with 'end-of-dose' motor fluctuations if another inhibitor of peripheral catechol-O-methyltransferase inappropriate (under expert supervision)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "100 mg 3 times a day (max. per dose 200 mg 3 times a day) continuing beyond 3 weeks only if substantial improvement, leave 6 hours between each dose; first daily dose should be taken at the same time as levodopa with dopa-decarboxylase inhibitor, dose maximum only in exceptional circumstances.",
                        "html": "<p>100&#8239;mg 3 times a day (max. per dose 200&#8239;mg 3 times a day) continuing beyond 3 weeks <b>only</b> if substantial improvement, leave 6 hours between each dose; first daily dose should be taken at the same time as levodopa with dopa-decarboxylase inhibitor, dose maximum only in exceptional circumstances.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Phaeochromocytoma",
                "html": "Phaeochromocytoma"
            },
            {
                "type": "contraindications",
                "textContent": "previous history of hyperthermia",
                "html": "previous history of hyperthermia"
            },
            {
                "type": "contraindications",
                "textContent": "previous history of neuroleptic malignant syndrome",
                "html": "previous history of neuroleptic malignant syndrome"
            },
            {
                "type": "contraindications",
                "textContent": "previous history of rhabdomyolysis",
                "html": "previous history of rhabdomyolysis"
            },
            {
                "type": "contraindications",
                "textContent": "severe dyskinesia",
                "html": "severe dyskinesia"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Most patients receiving more than 600 mg levodopa daily require reduction of levodopa dose by about 30%",
                "html": "Most patients receiving more than 600&#8239;mg levodopa daily require reduction of levodopa dose by about 30%"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Hepatotoxicity",
                "textContent": "Potentially life-threatening hepatotoxicity including fulminant hepatitis reported rarely, usually in women and during the first 6 months, but late-onset liver injury also reported; discontinue if abnormal liver function tests or symptoms of liver disorder; do not re-introduce tolcapone once discontinued.",
                "html": "<p>Potentially life-threatening hepatotoxicity including fulminant hepatitis reported rarely, usually in women and during the first 6 months, but late-onset liver injury also reported; discontinue if abnormal liver function tests or symptoms of liver disorder; do not re-introduce tolcapone once discontinued.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (tolcapone).",
                "html": "<p>Appendix 1 (tolcapone).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "anorexia",
                        "html": "anorexia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "chest pain",
                        "html": "chest pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "confusion",
                        "html": "confusion",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "drowsiness",
                        "html": "drowsiness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyskinesia",
                        "html": "dyskinesia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dystonia",
                        "html": "dystonia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "excessive dreaming",
                        "html": "excessive dreaming",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hallucinations",
                        "html": "hallucinations",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hepatotoxicity",
                        "html": "hepatotoxicity",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "sleep disturbances",
                        "html": "sleep disturbances",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "sweating",
                        "html": "sweating",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "syncope",
                        "html": "syncope",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "urine discoloration",
                        "html": "urine discoloration",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "xerostomia",
                        "html": "xerostomia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Neuroleptic malignant syndrome reported on dose reduction or withdrawal",
                        "html": "Neuroleptic malignant syndrome reported on dose reduction or withdrawal",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rhabdomyolysis reported on dose reduction or withdrawal",
                        "html": "rhabdomyolysis reported on dose reduction or withdrawal",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Toxicity in animal studies&#8212;use only if potential benefit outweighs risk.",
                "html": "<p>Toxicity in <i>animal</i> studies&#8212;use only if potential benefit outweighs risk.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;present in milk in animal studies.",
                "html": "<p>Avoid&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid.",
                "html": "<p>Avoid.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Caution if eGFR less than 30 mL/ minute/1.73 m2.",
                "html": "<p>Caution if eGFR less than 30&#8239;mL/ minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Test liver function before treatment, and monitor every 2 weeks for first year, every 4 weeks for next 6 months and then every 8 weeks thereafter (restart monitoring schedule if dose increased).",
                "html": "<p>Test liver function before treatment, and monitor every 2 weeks for first year, every 4 weeks for next 6 months and then every 8 weeks thereafter (restart monitoring schedule if dose increased).</p>"
            }
        ]
    },
    "treatmentCessation": {
        "treatmentCessation": [
            {
                "type": "treatmentCessation",
                "textContent": "Avoid abrupt withdrawal.",
                "html": "<p>Avoid abrupt withdrawal.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients should be told how to recognise signs of liver disorder and advised to seek immediate medical attention if symptoms such as anorexia, nausea, vomiting, fatigue, abdominal pain, dark urine, or pruritus develop.",
                "html": "<p>Patients should be told how to recognise signs of liver disorder and advised to seek immediate medical attention if symptoms such as anorexia, nausea, vomiting, fatigue, abdominal pain, dark urine, or pruritus develop.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76922",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1042",
                "label": "Tolcapone",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76922",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}